The first patient has been treated in an FDA-approved Investigational Device Exemption study for Moximed’s Atlas® unicompartmental unloading implant.
Atlas represents the latest iteration of technology employed in the KineSpring system for the treatment of medial knee osteoarthritis, providing the same 30 lbs. of joint unloading in a significantly smaller implant, with an anatomically-guided surgical technique.
In mid-2Q16, Moximed reported study results indicating that Atlas provided rapid, clinically-effective pain relief and an excellent safety profile in patients with early knee OA in the pre-arthroplasty disease stage.
The first patient has been treated in an FDA-approved Investigational Device Exemption study for Moximed's Atlas® unicompartmental unloading implant.
Atlas represents the latest iteration of technology employed in the KineSpring system for the treatment of medial knee osteoarthritis, providing the same 30 lbs. of joint unloading in a...
The first patient has been treated in an FDA-approved Investigational Device Exemption study for Moximed’s Atlas® unicompartmental unloading implant.
Atlas represents the latest iteration of technology employed in the KineSpring system for the treatment of medial knee osteoarthritis, providing the same 30 lbs. of joint unloading in a significantly smaller implant, with an anatomically-guided surgical technique.
In mid-2Q16, Moximed reported study results indicating that Atlas provided rapid, clinically-effective pain relief and an excellent safety profile in patients with early knee OA in the pre-arthroplasty disease stage.
Copy to clipboard 
